On June 28th, the official website of the Chinese National Medical Products Administration showed that CSPC Pharma's subsidiary, Ju Shi BioPharmaceutical's Class 1 new drug Enransubab injection was approved for listing in China. It is a PD-1 product used to treat recurrent or metastatic cervical cancer patients with PD-L1 expression who have failed at least first-line platinum-containing chemotherapy.
石药集团PD-1在国内获批
CSPC Pharma's PD-1 has been approved domestically in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.